Market Access Overview

Executive Summary

In Ireland, a Market Access Authorisation is submitted to the EMA to trigger the market access process. Pricing in Ireland is based on a cost-effectiveness threshold, guided by international referencing of the prices in 14 other countries. All products undergo a rapid review appraisal, and in some circumstances a full HTA as well.

Ireland has five reimbursement drug schemes which provide free or reduced healthcare services for citizens. The drug schemes differ depending on the type of treatment/illness.

This page provides a brief summary of pricing and reimbursement policies in Ireland, and describes the bodies responsible for decision making.